Combo Cobimetinib & Atezolizumab in Metastatic Colorectal Cancer 8Response Rate with an Overall Survival of 13-14 months

Combo Cobimetinib & Atezolizumab in Metastatic Colorectal Cancer 8Response Rate with an Overall Survival of 13-14 months

375 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Cathy Eng, MD, FACP GASTROINTESTINAL MEDICAL ONCOLOGY - MD Anderson discusses the combination of Cobimetinib & Atezolizumab in Metastatic Colorectal Cancer with an 8% Response Rate with an Overall Survival of 13-14 months. Recorded at ASCO GI 2018.
Up Next Autoplay